New melanoma treatment enters human testing
NCT ID NCT06214156
Summary
This early-stage study is testing a new drug called T3011 in people with advanced melanoma, a serious form of skin cancer. The main goals are to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. The study will enroll about 42 participants who have not responded to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact
-
Chengdu Shangjin Nanfu Hospital
RECRUITINGChengdu, China
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
Contact
-
Jilin Cancer Hospital
RECRUITINGChangchun, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGZhongshan, China
Contact
-
The First Affiliated Hospital of Bengbu Medical College
RECRUITINGBengbu, China
Contact
-
The Third People's Hospital of Zhengzhou
RECRUITINGZhengzhou, China
Contact
Conditions
Explore the condition pages connected to this study.